간편하게 보는 뉴스는 유니콘뉴스
QPS Announces New Global Clinical Research Operations Leadership

· 등록일 Jun. 21, 2024 13:40

· 업데이트일 2024-06-21 16:45:20

NEWARK, DEL.--(Business Wire / Korea Newswire)--QPS, a leading global contract research organization (CRO), is pleased to announce new clinical research operations leadership. This new clinical leadership will further align the existing global medical affairs, regulatory affairs, data services, and clinical operations units with the existing successful QPS Phase I clinics. The enhanced global capabilities will help QPS satisfy the need for agility, flexibility, and speed in the quickly evolving global drug development community.

QPS Holdings, LLC corporate headquarters in Delaware Technology Park in Newark, Delaware. This location is also the QPS Bioanalysis Laboratory Center of Excellence for small and large molecule drug development. (Photo: Business Wire) “This addition of Mr. Derek Grimes to the QPS Global Leadership Team will enhance our ability to collaborate across business units to offer comprehensive custom-built clinical development programs to better address a future dominated by Biologics and Advanced Therapy programs and a demand for accelerated clinical trials,” said Benjamin Chien, Chairman, President and CEO of QPS.

Mr. Derek Grimes, QPS Executive Vice President and Global Head of Clinical Research is a distinguished executive with 26 years of leadership experience in healthcare and clinical research across both academic and private institutions. He has played a pivotal role in developing complex healthcare and clinical research organizations and has been the operational lead on several hundred clinical research programs for academic and industry-based organizations. Grimes’ extensive experience and contributions to the field have made him a respected leader in clinical research and healthcare management. Most recently, Grimes served as the Senior Vice President of Clinical Operations at Frontage Laboratories, where he led the operations for the Clinical Services Division.

“I am excited to join the team and look forward to getting started. There is huge potential in the QPS full-service global CRO offering and enhanced alignment of leadership across the units will benefit our clients tremendously,” says Grimes.

In 2022, QPS announced a full transformation to a globally structured organization leading to seamless delivery of preclinical, bioanalytical, and clinical trial services around the world. At the same time, the organization formalized its medical affairs and regulatory affairs departments and onboarded new senior leaders for those teams. This enhanced structure has benefited our global customers, as our teams now more closely collaborate across all global regions. The addition of Grimes to this organization will further solidify QPS’ ability to serve Biotech and Pharmaceutical clients around the world.

ABOUT QPS HOLDINGS, LLC

QPS is a global, full-service, GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, bioanalysis, preclinical and clinical drug development services. Since 1995, QPS has grown from a small bioanalysis shop into a full-service CRO with 1,100+ employees in the US, Europe, and Asia. Today, QPS offers expanded pharmaceutical contract R&D services with special expertise in pharmacology, DMPK, toxicology, bioanalysis, translational medicine, clinical trials, and clinical research services. An award-winning leader focused on bioanalysis and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction, and turnkey laboratories and facilities. Through continual enhancements in capacities and resources, QPS stands tall in its commitment to delivering superior quality, skilled performance and trusted service to its valued customers. For more information, visit www.qps.com or email [email protected].

View source version on businesswire.com: https://www.businesswire.com/news/home/20240620868635/en/

Website: https://www.qps.com/ View Korean version of this release Contact QPS Holdings, LLC
Gabrielle Pastore
1-302-635-4290
[email protected]
This news is a press release provided by QPS Holdings, LLC. Korea Newswire follows these editorial guidelines. QPS Holdings, LLC News ReleasesSubscribeRSS QPS, 새로운 글로벌 임상 연구 운영 리더십 발표 선도적인 글로벌 임상시험 수탁기관(CRO)인 QPS가 새로운 임상 연구 운영 리더십을 발표했다. 이 새로운 임상 리더십은 기존의 글로벌 의학 부문, 규제 부문, 데이터 서비스, 임상 운영 단위를 기존의 성공적인 QPS 제1상 임상에 맞출 것으로 기대된다. QPS는 빠르게 변화하는 글로벌 약물 개발 커뮤니티에서 ... 13:40 QPS Expands Clinic in Miami, Florida to Accommodate Increasing Demand for Obesity Trials QPS, a leading global contract research organization (CRO), continues to expand and align its full-service preclinical, bioanalysis, and clinical capabilities with the evolution of demand for clinical trials. Today, QPS announced the expansion of its Miami, Florida Phase I clinical tria... 5월 22일 13:40 ... More  More News Health Clinical Trials Personnel Anouncement Overseas QPS Holdings, LLC All News Releases 
인기 기사05.17 11시 기준
부산--(뉴스와이어)--부산광역시장애인재활협회(회장 조덕자)가 부산시·KT 부산경남광역본부와 공동으로 주최한 ‘제20회 부산장애인정보화대제전(이하 BITC)’이 지난 6월 14일 장애인 참가자들의 높은 호응과 참여로 마무리됐다. 부산장애인재활협회 제20회 부산장애인정보화대제전 BITC ...
WARREN, N.J., & MUMBAI, INDIA--(Business Wire / Korea Newswire)--Fosfor, a product division of LTIMindtree [NSE: LTIM, BSE: 540005], a global technology consulting and digital solutions company, at its Foton 2024 event, announced the launch...
서울--(뉴스와이어)--인터넷 서점 알라딘은 독자들이 직접 투표로 선정하는 ‘2023 올해의 책’으로 무라카미 하루키의 ‘도시와 그 불확실한 벽’이 선정됐다고 12일 밝혔다. 알라딘의 독자들이 ‘2023 올해의 책’으로...
부천--(뉴스와이어)--청어학당(이사장 서성무)은 지난 2월 18일 ‘건강한 묘생 프로젝트 : 고양이와 함께하는 오닭만들기’ 행사를 부천 소재 청어학당 사무실에서 진행했다. 청어학당은 청소년과 청년들이 자발적 참여 속에 ‘고양이’를...
서울--(뉴스와이어)--건일제약(대표이사 이한국)이 2023년 11월 15일과 11월 23일 소아용불면증 치료제인 ‘슬리나이토 미니서방정1mg(멜라토닌)’, ‘슬리나이토 미니서방정5mg’의 신규 허가를 식품의약품안전처로부터 각각 획득했다고 밝혔다. 건일제약의 소아용 불면증 치료제 ‘슬리나이토 미니서방정’...
서울--(뉴스와이어)--좋은땅출판사가 ‘네오위버멘쉬를 위하여’를 펴냈다. 조석중 지음, 좋은땅출판사, 240쪽, 1만7000원 ‘사람 사는 세상’, ‘위로받지 않을 용기’ 등의 저서를 펼쳐 낸 조석중...
API
fg
유니콘뉴스는 보도자료 배포 서비스입니다.
여기에 뉴스를 등록하면 언론이 보도하고 널리 배포됩니다.